Abstract:Abstract Background Ulcerative colitis (UC) is a chronic inflammatory bowel disease characterised by colonic mucosa inflammation. Its clinical course is marked by alternating periods of relapse and remission that impair patients' quality of life. In the last decades, novel therapies have shown to be effective for UC resulting in lower rates of colectomy. However, there is still a significant proportion of non-responding patients that change from one treatment to another, being exposed to its potential adverse events. Thus, predictive factors of response to available drugs are needed to tailor the best treatment strategy for each patient. The aim of our study was to measure TNFα and IL-6 levels in colonic biopsies from patients with UC with moderate to severe endoscopic activity. Methods A prospective, observational single-centre study was designed and it is currently on going. Adult UC patients with moderate to severe endoscopic activity (Mayo Endoscopic Score (MES) > 1) in a routine colonoscopy were included. Biopsies from inflamed (MES>1) and non-inflamed (MES=0) colon of each patient were homogenised and processed by using RIPA buffer and ultrasounds to obtain cell lysates. Human Luminex Discovery Assay (2 plex) was used for the simultaneous detection and quantitation of IL-6 and TNFα. Data are shown as percentage, median, interquartile range (IQR) and mean ± standard deviation (SD) as appropriate. Results So far, 21 patients were consecutively included (mean age 53.8 years (SD 17.0), 52.4% female). About 43% of patients had left-sided UC, 28.5% extensive UC and 28.5% proctitis. Regarding endoscopic activity, 61.9% of patients showed MES=2 and 38.1% were MES=3. Fourteen patients (66.6%) were bio-naïve and 7 (33.3%) had been exposed to anti-TNFα. IL-6 was detected in biopsies from colon with MES ≥ 2 of 18 (85.7%) patients, of which 10 (55.6%) patients also TNFα was found. Neither IL-6 nor TNFα were detected in biopsies from non-inflamed colon (p=0.00). Median IL-6 in inflamed colonic samples from patients with MES-2 was 25.6pg/ml (IQR 0.2-74.3) and 92.2pg/ml (IQR 16.9-314.3) in those with MES-3 (p=0.09). Median TNFα in inflamed colonic biopsies from patients with MES-2 was 0.0pg/ml (IQR 0.0-20.0) and 22.2pg/ml (IQR 0.0-34.3) in patients with MES-3 (p=0.12) (Figure 1). No differences were found in TNFα levels between anti-TNFα naïve patients and those patients previously exposed to anti-TNFα (p=0.96). Conclusion IL-6 and TNFα are elevated in inflamed colonic mucosa, particularly in those patients with more severe endoscopic activity, while they are not found in non-inflamed colonic mucosa. The correlation between cytokine levels and endoscopic severity suggests their potential as biomarkers for treatment response.

Study of the activiation of IL-6 in patients with ulcerative colitis

Study of sIL-2R production from PBMCs in patients with ulcerative colitis

Effect of IL-12 on peripheral blood and lamina propria lymphocyte activation and proinflammatory cytokine secretion in patients with inflammatory bowel disease

In Vitro Production of TNFα, IL-6 and Sil-2R in Chinese Patients with Ulcerative Colitis

P083 JAK/STAT pathway and IL-6 activity in moderate to severe Ulcerative Colitis

Study on the Immune Modulator of Patients with Ulcerative Colitis

The Expressions of IL-2, IL-4, IL-17 and IL-10 in Ulcerative Colitis (UC) Mucosa and Its Relation with Disease Activity

Immune Regulation of Interleukin-23 on Peripheral Blood Natural Killer Cell in Patients with Inflammatory Bowel Disease

Role of IL-6 in the imbalance of Th17/Treg in DSS-induced ulcerative colitis mice

Increased Expression of Interleukin-23 Induces Proinflammatory Cytokine Secretion in Inflammatory Bowel Disease

Determination of serum TNF-α and IL-8 in patients with inflammatory bowel disease

Effect of IL-18 on Peripheral Blood and Lamina Propria Lymphocyte Prolif Eration and Proinflammatory Cytokine Secretion in Patients with Inflammatory Bowel Disease

Clinical significance of expression of peroxisome proliferator-activated receptor γ coactivator 1α in the inflamed mucosa of patients with inflammatory bowel disease

Clinical Significance and Assessment of Cytokines in Various Stages of Ulcerative Colitis

The Expression of HBD-2, NF-kB, IL-6 and IL-23 in Colonic Mucosa of Ulcerative Colitis and Irritable Bowel Syndrome

IL-6 Production Stimulated by CD14(+) Monocytes-Paracrined IL-1β Does Not Contribute to the Immunosuppressive Activity of Human Umbilical Cord Mesenchymal Stem Cells.

P021 Higher TNFα and IL-6 mucosal levels in ulcerative colitis patients with more severe endoscopic activity

Clinical Significance of Lymphocyte Subsets Changes in the Active Stage of Ulcerative Colitis: a Retrospective Study

[Activation of Nuclear Factor-Kappab and Its Relationship with Cytokine Gene Expression in Colonic Mucosa of Ulcerative Colitis Patients].

Activation of CD40-CD154 Co-Stimulatory Pathway and Its Correlation with Disease Activity in Patients with Inflammatory Bowel Disease

Identification of immune cell markers associated with ulcerative colitis histological disease activity in colonic biopsies